-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$257.50-21.93% Downside
Karuna Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Karuna Therapeutics, Inc.?
Karuna Therapeutics, Inc. has been rated by research analysts at H.C. Wainwright, Piper Sandler, Guggenheim, Stifel Nicolaus, Mizuho Securities, Maxim Group in the past 90 days.